Test Code EBVP EBV Antibody Panel
EHR Test Codes
| Test Code | Test Name | |
| Atlas | EBVP | EBV Antibody Panel |
| Cerner | EBV Antibody Panel |
Specimen Requirements
Preparation of Patient:
None
Container Type:
Gold Top 6mL SST Gel & Clot Activator Tube
Specimen Type:
Serum
Specimen Volume:
2.5 mL Serum minimum 0.3 mL
Specimen Handling/Transport:
Transport refrigerated 2 - 8°C
Specimen Stability/Storage:
2 days refrigerated 2 - 8°C
Specimen Rejection:
Gross hemolysis
Gross lipemia
Gross icterus
Performing Laboratory
Munson Medical Center Laboratories
Chemistry Department
Priority, Frequency, & Turnaround
Priority:
Non-Emergent
Frequency:
Wednesday
Turnaround:
0 - 7 days
Methodology
Chemiluminescence Immunoassay
Panel Includes: EBV, IgM, Early Antigen (EA IgG), Epstein-Barr Nuclear Antigen (EBNA), and Viral Capsid Antigen (VCA, IgG)
Reporting
Reference Range:
Negative
Interpretive Data:
Equivocal sample should be repeat tested. In case the result remains in the range after repeat testing, a second sample should be collected and tested no less than one or two weeks later.
Flow Diagram:
The accurate distinction of a primary (acute) infection from seronegative status or past infection is a key concern of EBV diagnostics. The presence of other EBV serological markers (e.g. EBV IgM, VCA IgG, EBNA IgG) should be determined to assess the immunological status to infection with EBV. Based on the results of three commonly-used antibody tests (VCA IgG, EBV IgM, EBNA IgG), distinct serological profiles have been described in the medical literature.
| Condition | VCA IgG | EBV IgM | EBNA IgG |
| EBV seronegative | - | - | - |
| Primary (acute) infection | + | + | - |
| Past infection | + | - | _ |
| Indeterminate | |||
| VCA IgG only | + | - | - |
| EBV IgM only | - | + | - |
| EBNA IgG only | - | - | + |
| Convalescent | + | + | + |
Because some individuals are reported to exhibit long-lasting EBV IgM antibodies, the convalescent pattern may represent a transient period late in the primary infection stage or may persist well into the past infection stage. Thus, it is considered an indeterminate pattern. For samples that exhibit indeterminate patterns, further diagnostic testing may be required. In all cases, diagnosis of infectious diseases should not be established on the basis of a single test result, but should be determined in conjunction with clinical findings and other diagnostic procedures as well as in association with medical judgment
Critical Decision:
None
Clinical Significance
Epstein-Barr virus (EBV) is responsible for infectious mononucleosis (IM) and is implicated in Burkitt's lymphoma and nasopharyngeal carcinoma. Antibody response profiles for the different EBV antigens demonstrate a characteristic pattern for silent primary or persistent latent EBV infections, as well as for each of the EBV-associated diseases.
CPT Code(s)
86663
86664
86665